Impact ofHelicobacter pyloriinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors

• DOI: 10.1136/jitc-2023-007699
• Publication Date: 2023-10-30T01:17:01Z
• Authors: Patrick T Magahis; Steven B Maron; Darren Cowzer; Stephanie King; Mark Schattner; Yelena Janjigian; David Faleck; Monika Laszkowska
• Keywords: Histopathology

Background Gut microbiota composition can influence cancer immunotherapy response. Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint inhibitor (ICI) efficacy in lung and melanoma, but thorough characterization of this association patients with gastric is lacking. We aimed to determine the impact H. on survival population. Methods This single-center, retrospective study included all ICI-treated individuals metastatic documented status at Memorial Sloan Kettering between July 2013 October 2021. -positive was defined as history obtained via breath test, stool antigen histopathology, and/or chart documentation. Negative explicitly negative testing, Primary outcomes were progression-free (PFS) overall (OS). Results Of 215 patients, 49 had infection. Compared pylori- positive tended be younger, non-white, Hispanic non-cardia intestinal-type cancer. significantly shorter median PFS (3.2 vs 6.8 months, HR 1.96, p<0.01) OS (9.8 17.9 1.54, p=0.02). Multivariable analysis confirmed an independent predictor (HR 3.04, 2.24, p=0.01). Conclusions In largest its kind, associated inferior a prognostic marker responsiveness. Future studies are needed elucidate immunoregulatory mechanisms whether treatment active infections would improve outcomes.